ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...

The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses ...

ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug ...

CK0804 is a first in class, CXCR4hi Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over ...

OBJECTIVES: To identify risk factors for DMF-induced lymphopenia and characterize its impact on T lymphocyte subsets in MS patients. METHODS: We performed a retrospective analysis of 194 RRMS patients ...

An elevated neutrophil-to-lymphocyte ratio (NLR) is significantly associated with increased risk of depressive disorder (DD) ...

An elevated neutrophil-to-lymphocyte ratio (NLR) is significantly associated with increased risk of depressive disorder (DD) ...